CLINICAL TRIALS PROFILE FOR INVOKANA
✉ Email this page to a colleague
All Clinical Trials for INVOKANA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01877889 ↗ | A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers | Completed | Janssen-Cilag International NV | Phase 1 | 2013-07-01 | The purpose of this study is to compare the pharmacodynamics (ie, how the drug affects the body) of canagliflozin with the pharmacodynamics of dapagliflozin. |
| NCT01916863 ↗ | Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects | Completed | Lexicon Pharmaceuticals | Phase 1 | 2013-08-01 | The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo. |
| NCT02009488 ↗ | Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) | Completed | Janssen Research & Development, LLC | Phase 1 | 2014-09-08 | The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic (blood sugar) control on metformin monotherapy or on combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for INVOKANA
Condition Name
Clinical Trial Locations for INVOKANA
Trials by Country
Clinical Trial Progress for INVOKANA
Clinical Trial Phase
Clinical Trial Sponsors for INVOKANA
Sponsor Name
